DiscGenics, Inc.   Report issue

For profit Phase 2
Founded: Salt Lake City UT United States (2007)

Organization Overview

First Clinical Trial
2018
NCT03347708
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

DiscGenics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

discogenic cells (2 trials)

hyaluronic acid (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Intervertebral Disc Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2